Browsing Tag
HER2 breast cancer
2 posts
BioNTech stock jumps 8.66% after DB-1303 meets primary endpoint in breast cancer trial
BioNTech stock surged after DB-1303 met its Phase 3 endpoint in HER2-positive breast cancer. Find out what this means for global oncology strategy.
Imagion Biosystems (ASX: IBX) soars 84% after FDA feedback on HER2 breast cancer trial
Imagion Biosystems surged 84% on FDA feedback for its breast cancer imaging trial. Find out what this means for its MagSense tech and investor outlook.